Clinical Trial Update: Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of ridaforolimus (MK-8669) in Chinese participants has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Advanced

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cancer, Advanced | Phase 1 | Status: COMPLETED | Results posted: 2019-04-19